Page 19 - Read Online

Page 14 of 14 Atmaja et al. J Cancer Metastasis Treat 2021;7:xx https://dx.doi.org/10.20517/2394-4722.2021.66

70. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic
renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404-15. DOI
PubMed
71. Al-Marrawi MY, Rini BI, Harshman LC, et al. International mRCC Database Consortium. The association of clinical outcome to first-
line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
Target Oncol 2013;8:203-9. DOI PubMed PMC
72. Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3,
multicentre, randomised, controlled, open-label study. Lancet 2020;21:95-104. DOI PubMed
73. Zakharia Y, Singer EA, Ross R, Joshi M, Alva AS. Phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer Big
Ten Cancer Research Consortium BTCRC GU16-043. JCO 2021;39:328. DOI
74. Choueiri TK, Bauer TM, Mcdermott DF, et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in
combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol 2021;39:272. DOI
75. Kollmannsberger C. Sunitinib side effects as surrogate biomarkers of efficacy. Can Urol Assoc J 2016;10:S245-7. DOI PubMed
PMC
76. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with
sunitinib. J Natl Cancer Inst 2011;103:763-73. DOI PubMed PMC
77. Wasserstrum Y, Kornowski R, Raanani P, Leader A, Pasvolsky O, Iakobishvili Z. Hypertension in cancer patients treated with anti-
angiogenic based regimens. Cardiooncology 2015:7;1-6. DOI PubMed PMC
78. Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol
2012;23:973-80. DOI PubMed
79. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-6. DOI
PubMed
80. Wang CJ, Christie A, Lin MH, et al. Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial
metastases. Int J Radiat Oncol Biol Phys 2017;98:91-100. DOI PubMed PMC
81. Aoun HD, Littrup PJ, Jaber M, et al. Percutaneous cryoablation of renal tumors: is it time for a new paradigm shift? J Vasc Interv
Radiol 2017;28:1363-70. DOI PubMed
82. Mehta S, Illidge T, Choudhury A. Immunotherapy with radiotherapy in urological malignancies. Curr Opin Urol 2016;26:514-22.
DOI PubMed
83. EurekAlert! AAAS. No benefit from Pazopanib in advanced kidney cancer after surgery to remove metastases. Available from:
https://www.eurekalert.org/pub_releases/2019-06/ecrg-nbf053119.php [Last accessed on 3 Jun 2021].